<i>In silico</i> structural analysis of carbapenemase variants in <i>Klebsiella pneumoni</i> ae: insights for precision drug discovery against multidrug-resistant strains

These results reinforce that <i>Klebsiella pneumoniae</i> carbapenemases are not interchangeable targets and that inhibitor design must account for family-specific active-site geometries and dynamics. Integrating such structural insight with future virtual screening and experimental validation could enable variant-tailored inhibitors rather than relying on a single broad-spectrum carbapenemase blocker.